[1] Meazza C, Scanagatta P. Metastatic osteosarcoma: a challenging multidisciplinary treatment [J]. Expert Rev Anticancer Ther, 2016, 16:543-556. [2] Dean DC, Shen S, Hornicek FJ, et al. From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma[J]. Cancer Metastasis Rev, 2018, 37:719-731. [3] Klaschik K, Hauke J, Neidhardt G, et al. The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers[J]. Int J Cancer, 2019, 144:1761-1763. [4] 伍龙,袁静萍,叶俊杰,等.基于数据挖掘分析GPRC5A在胰腺癌中的表达及意义[J].临床与病理杂志, 2019, 39:252-261. [5] Zhou H, Rigoutsos I. The emerging roles of GPRC5A in diseases[J]. Oncoscience, 2014, 1:765-776. [6] 张文静,邓文彬,秦鑫.转录因子调控EMT参与肿瘤侵袭和转移[J].基础医学与临床, 2016, 36:272-276. [7] Mittal V. Epithelial mesenchymal transition in tumor metastasis[J]. Annu Rev Pathol, 2018, 13:395-412. [8] Dean DC, Shen S, Hornicek FJ, et al. From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma[J]. Cancer Metastasis Rev, 2018, 37:719-731. |